(4R,5S)-3-((R)-2-isopropylpent-4-enoyl)-4-methyl-5-phenyloxazolidin-2-one | 877078-55-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑烷类
• 英文名称: (4R,5S)-3-((R)-2-isopropylpent-4-enoyl)-4-methyl-5-phenyloxazolidin-2-one
• 英文别名: (4R,5S)-4-methyl-5-phenyl-3-[(2R)-2-propan-2-ylpent-4-enoyl]-1,3-oxazolidin-2-one
• CAS: 877078-55-2
• 化学式: C₁₈H₂₃NO₃
• 分子量: 301.386
• InChiKey: HYHZPIZGSFIASS-FVQBIDKESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  22
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  46.6
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (4R,5S)-3-((R)-2-isopropylpent-4-enoyl)-4-methyl-5-phenyloxazolidin-2-one 在 N-甲基吗啉 、 HATU 、 双氧水 、 臭氧 、 lithium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 水 、 N,N-二甲基甲酰胺 为溶剂， 生成
  参考文献：
  名称：

  Monosubstituted γ-lactam and conformationally constrained 1,3-diaminopropan-2-ol transition-state isostere inhibitors of β-secretase (BACE)

  摘要：

  The synthesis, evaluation, and structure-activity relationships of a class of gamma-lactam 1,3-diaminopropan-2-ol transition-state isostere inhibitors of BACE are discussed. Two strategies for optimizing lead compound 1a are presented. Reducing the overall size of the inhibitors resulted in the identification of gamma-lactam 1i, whereas the introduction of conformational constraint on the prime-side of the inhibitor generated compounds such as the 3-hydroxypyrrolidine inhibitor 28n. The full in vivo profile of 1i in rats and 28n in Tg 2576 mice is presented. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.06.109
• 作为产物：
  描述：

  (4R,5S)-(+)-4-甲基-5-苯基-2-恶唑啉酮 在 正丁基锂 、 sodium hexamethyldisilazane 作用下， 以 四氢呋喃 为溶剂， 反应 12.25h， 生成 (4R,5S)-3-((R)-2-isopropylpent-4-enoyl)-4-methyl-5-phenyloxazolidin-2-one
  参考文献：
  名称：

  感应远程手性：立体化学测定β-，γ-和δ-手性羧酸

  摘要：

  确定带有远程不可官能化立体中心的小分子的绝对立体化学是一项艰巨的任务。提出了一种使用适当取代的双（卟啉）镊子的溶液。适当地衍生化的β-，γ-或δ-手性羧酸与镊子的络合可诱导双卟啉的可预测螺旋度，这被检测为二元棉花效应（ECCD）。ECCD曲线的符号基于派生的工作助记符以可预测的方式与基材的绝对立体化学相关。

  DOI：

  10.1002/anie.201410371

文献信息

• Novel gamma-lactams as beta-secretase inhibitors
  申请人：Thompson A. Lorin

  公开号：US20060046984A1

  公开（公告）日：2006-03-02

  There is provided a series of novel substituted gamma-lactams of Formula (I) or a stereoisomer; or a pharmaceutically acceptable salt thereof, wherein R 1 , R 2 , R 4 , R 5 and R 6 as defined herein, their pharmaceutical compositions and methods of use. These novel compounds inhibit the processing of amyloid precursor protein (APP) by β-secretase and, more specifically, inhibit the production of Aβ-peptide. The present disclosure is directed to compounds useful in the treatment of neurological disorders related to β-amyloid production, such as Alzheimer's disease and other conditions affected by anti-amyloid activity.

  提供了一系列新型取代的γ-内酰胺，化学式为(I)或其立体异构体；或其药用盐，其中R1、R2、R4、R5和R6如本文所定义，它们的药用组合物和使用方法。这些新型化合物抑制β-分泌酶对淀粉样前体蛋白（APP）的加工，更具体地抑制Aβ肽的产生。本公开涉及对β-淀粉样蛋白产生相关的神经系统疾病的治疗有用的化合物，如阿尔茨海默病和其他受抗淀粉样活性影响的疾病。
• Conformational Preference in Bis(porphyrin) Tweezer Complexes: A Versatile Chirality Sensor for α-Chiral Carboxylic Acids
  作者：Marina Tanasova、Babak Borhan

  DOI：10.1002/ejoc.201200147

  日期：2012.6

  determinant of binding conformation. Experimental results indicate that a balance between linker flexibility and rigidity could yield an optimum porphyrin tweezer that stabilizes a common conformation for all bound chiral guests. This leads to a more simplified approach to absolute stereochemical determination of asymmetry for small organic molecules. This was demonstrated by the use of a C3-linked zincated

  金属化卟啉镊子已表现出非凡的能力，可以作为许多不同类别有机分子的绝对立体化学报告者。然而，结合的灵活性可能导致不同激子耦合圆二色性 (ECCD) 活性构象的集合，这可能导致可变的结果。发现接头灵活性是结合构象的关键决定因素。实验结果表明，接头柔韧性和刚性之间的平衡可以产生最佳的卟啉镊子，稳定所有结合手性客体的共同构象。这导致了一种更简单的方法来确定小有机分子的不对称性的绝对立体化学。
• US7388007B2
  申请人：——

  公开号：US7388007B2

  公开（公告）日：2008-06-17
• [EN] NOVEL GAMMA-LACTAMS AS BETA-SECRETASE INHIBITORS<br/>[FR] NOUVELLES GAMMA-LACTAMES SERVANT D'INHIBITEURS DE BETA-SECRETASE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2006026204A2

  公开（公告）日：2006-03-09

  There is provided a series of novel substituted gamma-lactams of Formula (I) or a stereoisomer; or a pharmaceutically acceptable salt thereof, wherein R1, R2, R4 , R5, and R6 as defined herein,their pharmaceutical compositions and methods of use. These novel compounds inhibit the processing of amyloid precursor protein (APP) by beta-secretase and, more specifically, inhibit the production of alpha-beta -peptide. The present disclosure is directed to compounds useful in the treatment of neurological disorders related to beta-amyloid production, such as Alzheimer's disease and other conditions affected by anti-amyloid activity.